Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Randox Laboratories Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows a level of diversification in the prosecution process, with 2 distinct examiners reviewing the company's applications. This spread means that the company's patenting success is subject to the review of different individuals.
WESTERBERG, NISSA M is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending action. With 2 pending office actions in total, the workload is spread across these examiners. This means that no individual examiner has a majority of the active cases, which suggests a prosecution environment where different perspectives are applied to the company's innovations.
Practitioners should observe that the 2 distinct art units involved indicate that the company's innovations are being evaluated under different sets of technical criteria. The current volume of pending office actions indicates the level of activity. The spread across these examiners requires a strategy that accounts for different perspectives within the patent office, as each examiner may have unique interpretations of biotechnology patentability. Strategies for this portfolio are currently dependent on the specific requirements and tendencies of WESTERBERG, NISSA M.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| MONTGOMERY, ANN Y | 1 | 69.0% | +27.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | WESTERBERG, NISSA M | 9d |
| 17294358 | DETECTION OF BLADDER CANCER | MONTGOMERY, ANN Y | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | WESTERBERG, NISSA M | 9d |
| 17294358 | DETECTION OF BLADDER CANCER | MONTGOMERY, ANN Y | 28d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17775217 | BIOMARKER OF DRUG-INDUCED CELLULAR TOXICITY AND DEPRESSION | WESTERBERG, NISSA M | 1618 | §101§103§112 | Final Rejection | 9d | Pending | May 06, 2022 |
| 17294358 | DETECTION OF BLADDER CANCER | MONTGOMERY, ANN Y | 1678 | §101§103 | Non-Final OA | 28d | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial